Cargando…

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus

PURPOSE: New-onset diabetes after transplantation (NODAT) is a major complication after kidney transplantation. The risk factors for NODAT include the use of calcineurin inhibitors as part of the immunosuppressive regimen, among which tacrolimus has the most pronounced diabetogenic effect. Both NODA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurzawski, Mateusz, Dziewanowski, Krzysztof, Łapczuk, Joanna, Wajda, Anna, Droździk, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Pharmacogenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496482/ https://www.ncbi.nlm.nih.gov/pubmed/22569928 http://dx.doi.org/10.1007/s00228-012-1292-8

Ejemplares similares

Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography
por: Banaś, Anna, et al.
Publicado: (2011)

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
por: de Wildt, Saskia N., et al.
Publicado: (2011)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
por: Wu, Yi, et al.
Publicado: (2021)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
por: Dziedziejko, Violetta, et al.
Publicado: (2011)

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis
por: Łączna, Małgorzata, et al.
Publicado: (2021)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
por: Wattanachai, Nitsupa, et al.
Publicado: (2017)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study
por: Andreassen, Trine Naalsund, et al.
Publicado: (2011)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
por: O'Meara, Helen, et al.
Publicado: (2014)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan
por: Shimazawa, R, et al.
Publicado: (2014)

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
por: Trompet, S., et al.
Publicado: (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
por: Vizeli, Patrick, et al.
Publicado: (2017)

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
por: Liu, Mengyuan, et al.
Publicado: (2020)

Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients
por: Preissner, Sally H., et al.
Publicado: (2021)

Antibacterial performance of nanocrystallined titania confined in mesoporous silica nanotubes
por: Cendrowski, Krzysztof, et al.
Publicado: (2014)

Fast Tacrolimus Metabolism Does Not Promote Post-Transplant Diabetes Mellitus after Kidney Transplantation
por: Jehn, Ulrich, et al.
Publicado: (2022)

Kidney Drug Transporters in Pharmacotherapy
por: Łapczuk-Romańska, Joanna, et al.
Publicado: (2023)

Hepatic drug-metabolizing enzymes and drug transporters in Wilson’s disease patients with liver failure
por: Szeląg-Pieniek, Sylwia, et al.
Publicado: (2021)

The reference liver—CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype
por: Kurzawski, Mateusz, et al.
Publicado: (2021)

Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression
por: Baron, Pedro W., et al.
Publicado: (2017)

Association study of folate-related enzymes (MTHFR, MTR, MTRR) genetic variants with non-obstructive male infertility in a Polish population
por: Kurzawski, Mateusz, et al.
Publicado: (2015)

New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT
por: Iida, Shoichi, et al.
Publicado: (2010)

New-Onset Diabetes Mellitus in Post-renal Transplant Patients on Tacrolimus and Mycophenolate: A Systematic Review
por: Nandula, Savitri Aninditha, et al.
Publicado: (2022)

Post-transplant Diabetes Mellitus in Kidney Transplant Recipients in Sudan: A Comparison Between Tacrolimus and Cyclosporine-Based Immunosuppression
por: Yousif, Elamein, et al.
Publicado: (2022)

Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
por: Drozdzik, Marek, et al.
Publicado: (2021)

Diabetes Mellitus in the Transplanted Kidney
por: Peev, Vasil, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6r5metmlv85rnai6fttli714bq